Sotera Health (NASDAQ:SHC) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Key Points

• JPMorgan cut Sotera Health’s price target from $17 to $15 and maintained an “underweight” rating, implying 8.56% downside from the prior close.
• Analyst views are more positive overall: MarketBeat reports a “Moderate Buy” consensus and an average price target of $20.88, with eight Buy, two Hold and one Sell rating.
• Sotera Health beat quarterly estimates, reporting $0.29 EPS versus $0.27 expected and revenue of $324.9 million, up 4.4% year over year.

Sotera Health (NASDAQ:SHC - Get Free Report) had its price target cut by investment analysts at JPMorgan Chase & Co. from $17.00 to $15.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential downside of 8.56% from the company's previous close.

SHC has been the topic of a number of other research reports. Weiss Ratings downgraded shares of Sotera Health from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, October 23rd. Piper Sandler restated an "overweight" rating and issued a $25.00 price objective on shares of Sotera Health in a report on Tuesday, September 8th. Citigroup lifted their price objective on Sotera Health from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Wall Street Zen upgraded Sotera Health from a "buy" rating to a "strong-buy" rating in a report on Sunday, October 25th. Finally, Barclays dropped their target price on shares of Sotera Health from $22.00 to $20.00 and set an "overweight" rating for the company in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Sotera Health has a consensus rating of "Moderate Buy" and a consensus price target of $20.88.

Sotera Health Trading Up 2.3%

NASDAQ:SHC traded up $0.38 during mid-day trading on Wednesday, reaching $16.41. The company's stock had a trading volume of 3,015,531 shares, compared to its average volume of 2,704,585. The company's fifty day simple moving average is $18.42 and its two-hundred day simple moving average is $17.02. The company has a debt-to-equity ratio of 3.33, a current ratio of 2.80 and a quick ratio of 2.55. Sotera Health has a twelve month low of $13.09 and a twelve month high of $19.85. The stock has a market cap of $4.68 billion, a P/E ratio of 28.81 and a beta of 1.94.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The company had revenue of $324.89 million during the quarter, compared to analysts' expectations of $319.86 million. During the same quarter in the previous year, the business earned $0.26 EPS. The firm's revenue was up 4.4% on a year-over-year basis. On average, equities analysts predict that Sotera Health will post 0.87 EPS for the current year.

Insider Activity

In other news, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the sale, the chairman owned 3,969,393 shares in the company, valued at approximately $73,433,770.50. This trade represents a 17.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael P. Rutz sold 150,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $18.84, for a total value of $2,826,000.00. Following the sale, the insider owned 334,279 shares in the company, valued at approximately $6,297,816.36. The trade was a 30.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,294,515 shares of company stock valued at $23,999,528 in the last ninety days. Company insiders own 15.36% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SHC. AlphaCore Capital LLC raised its holdings in Sotera Health by 50.7% in the third quarter. AlphaCore Capital LLC now owns 18,751 shares of the company's stock valued at $347,000 after acquiring an additional 6,307 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Sotera Health by 7.3% during the 3rd quarter. Retirement Systems of Alabama now owns 294,348 shares of the company's stock valued at $5,442,000 after acquiring an additional 20,050 shares during the last quarter. Ethic Inc. grew its holdings in Sotera Health by 12.7% during the 3rd quarter. Ethic Inc. now owns 12,521 shares of the company's stock worth $232,000 after acquiring an additional 1,413 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Sotera Health by 13.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 43,252 shares of the company's stock worth $800,000 after acquiring an additional 5,189 shares in the last quarter. Finally, Alps Advisors Inc. bought a new stake in shares of Sotera Health in the 3rd quarter worth about $579,000. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Sotera Health News Summary

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q3 revenue rose 4.4% year over year to $324.9 million, topping analyst expectations of about $319.9 million. Adjusted EPS was $0.29 versus the $0.27 consensus and increased 12% year over year; adjusted EBITDA rose 3.9%. Sotera Health Q3 results
• Neutral Sentiment: Management reaffirmed its 2026 outlook: constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. It also provided fourth-quarter revenue guidance, though the supplied report did not include the forecast figure. Fourth-quarter revenue guidance
• Negative Sentiment: The company cited softness in the European medical-device market, a demand headwind investors will monitor despite the reaffirmed full-year targets. 2026 outlook and European market conditions

About Sotera Health

Sotera Health Company NASDAQ: SHC is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.